Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 4, 2013, Pages 451-457

  Løken Amsrud, Kristin I ^a,b   Myhr, Kjell Morten ^c,d   Bakke, Søren J ^e   Beiske, Antonie G ^f   Bjerve, Kristian S ^g,h   Bjørnarå, Bård T ⁱ   Hovdal, Harald ^g   Lilleås, Finn ⁱ   Midgard, Rune ^h,j   Pedersen, Tom ^k   Benth, Jurate Šaltyte ^b,l   Torkildsen, Øivind ^c   Wergeland, Stig ^c   Holmøy, Trygve ^b,l  

^a INNLANDET HOSPITAL TRUST   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f Multiple Sclerosis Centre Hakadal   (Norway)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^h NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

ⁱ Department of Laboratory Medicine Children's and Women's Health Norwegian University of Science and Technology ^*  (Norway)

^j Molde Hospital   (Norway)

^k Unilabs   (France)

^l AKERSHUS UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Cohort studies; Demyelinating diseases; Magnetic resonance imaging; Multiple sclerosis; Vitamin A

Indexed keywords

25 HYDROXYVITAMIN D; BETA1A INTERFERON; DOCOSAHEXAENOIC ACID; HLA DRB1 ANTIGEN; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; RETINOL; TRIOMAR; UNCLASSIFIED DRUG;

ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; VITAMIN BLOOD LEVEL;

EID: 84877849015     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512457843     Document Type: Article

References (35)

1. Mora JR, Iwata M and von Andrian UH. Vitamin effects on the immune system: Vitamins A and D take centre stage. Nat Rev Immunol 2008; 8: 685-698.
2. Kim CH. Retinoic acid, immunity, and inflammation. Vitam Horm 2011; 86: 83-101.
3. Ross AC, Chen Q and Ma Y. Vitamin A and retinoic acid in the regulation of B-cell development and antibody production. Vitam Horm 2011; 86: 103-126.
4. Farso MC, Krantic S, Rubio M, et al. The retinoid, 6-[3-adamantyl-4- hydroxyphenyl]-2-napthalene carboxylic acid, controls proliferative, morphological, and inflammatory responses involved in microglial activation without cytotoxic effects. Neuroscience 2011; 192: 172-184.
5. Racke MK, Burnett D, Pak SH, et al. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol 1995; 154: 450-458.
6. Massacesi L, Abbamondi AL, Giorgi C, et al. Suppression of experimental allergic encephalomyelitis by retinoic acid. J Neurol Sci 1987; 80: 55-64. (Pubitemid 17094624)
7. Pombo PMG, Barettino D, Ibarrola N, et al. Stimulation of the myelin basic protein gene expression by 9-cis-retinoic acid and thyroid hormone: Activation in the context of its native promoter. Brain Res Mol Brain Res 1999; 64: 92-100. (Pubitemid 29049240)
8. Huang JK, Jarjour AA, Oumesmar BN, et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci 2011; 14: 45-53.
9. Jimenez-Lara AM and Aranda A. Interaction of vitamin D and retinoid receptors on regulation of gene expression. Horm Res 2000; 54: 301-305. (Pubitemid 34701738)
10. Torkildsen Ø, Wergeland S, Bakke SJ, et al. Omega-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS study): A randomised, double-blind, placebo-controlled trial. Arch Neurol. Epub ahead of print 16 April 2012. DOI: 10.1001/archneurol.2012.283.
11. Løken-Amsrud KI, Holmøy T, Bakke SJ, et al. Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. Neurology. 2012; 79: 267-273.
12. Lindberg M, Saltvedt I, Sletvold O, et al. Long-chain n-3 fatty acids and mortality in elderly patients. Am J Clin Nutr 2008; 88: 722-729.
13. Wong GY and Mason WM. The hierarchical logistic regression model for multilevel analysis. J Am Stat Assoc 1985; 80: 513-524.
14. Qu ZX, Dayal A, Jensen MA, et al. All-trans retinoic acid potentiates the ability of interferon beta-1b to augment suppressor cell function in multiple sclerosis. Arch Neurol 1998; 55: 315-321. (Pubitemid 28146196)
15. Simpson JL, Bailey LB, Pietrzik K, et al. Micronutrients and women of reproductive potential: Required dietary intake and consequences of dietary deficienty or excess. Part II - vitamin D, vitamin A, iron, zinc, iodine, essential fatty acids. J Matern Fetal Neonatal Med 2010; 24: 1-24.
16. Eager NSC, Brickell PM, Snell C, et al. Structural and functional evidence for activation of a chick retinoid X receptor by eicosanoids. Proc Biol Sci 1992; 250: 63-69.
17. Radominska-Pandya A and Chen G. Photoaffinity labeling of human retinoid X receptor beta (RXRbeta) with 9-cis-retinoic acid: Identification of phytanic acid, docosahexaenoic acid, and lithocholic acid as ligands for RXRbeta. Biochemistry 2002; 41: 4883-4890. (Pubitemid 34298655)
18. Mehta LR, Dworkin RH and Schwid SR. Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nat Clin Pract Neurol 2009; 5: 82-92.
19. Hedström AK, Sundqvist E, Bäärnhielm M, et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 2011; 134: 653-664.
20. Ramagopalan SV, Maugeri NJ, Handunnetthi L, et al. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009; 5: e1000369.
21. Zhang SM, Hernan MA, Olek MJ, et al. Intakes of carotenoids, vitamin C, and vitamin E and MS risk among two large cohorts of women. Neurology 2001; 57: 75-80. (Pubitemid 32634853)
22. Harrison EH. Mechanisms of digestion and absorption of dietary vitamin A. Annu Rev Nutr 2005; 25: 87-103. (Pubitemid 41208995)
23. Royal W, Gartner S and Gajewski CD. Retinol measurements and retinoid receptor gene expression in patients with multiple sclerosis. Mult Scler 2002; 8: 452-458. (Pubitemid 35396391)
24. Besler HT, Comoglu S and Okcu Z. Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis. Nutr Neurosci 2002; 5: 215-220. (Pubitemid 34568217)
25. Karg E, Klivenyi P, Nemeth I, et al. Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol 1999; 246: 533-539. (Pubitemid 29376276)
26. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-retinoic acid and interferon alpha-2a: Effective combination. Therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992; 84: 235-241.
27. Tanumihardjo SA. Vitamin A: Biomarkers of nutrition for development. Am J Clin Nutr 2011; 94: 658S-665S.
28. Blomhoff R and Blomhoff HK. Overview of retinoid metabolism and function. J Neurobiol 2006; 66: 606-630. (Pubitemid 43941649)
29. Stephensen CB and Gildengorin G. Serum retinol, the acute phase response, and the apparent misclassification of vitamin A status in the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2000; 72: 1170-1178.
30. Soilu-Hänninen M, Koskinen JO, Laaksonen M, et al. High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology 2005; 65: 153-155. (Pubitemid 40967796)
31. Giovannoni G, Thorpe JW, Kidd D, et al. Soluble E-selectin in multiple sclerosis: Raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry 1996; 60: 20-26. (Pubitemid 26012262)
32. Sørensen PS. Biological markers in body fluids for activity and progression in multiple sclerosis. Mult Scler 1999; 5: 287-290. (Pubitemid 29405627)
33. Zhou R, Horai R, Mattapallil MJ, et al. A new look at immune privilege of the eye: Dual role for the vision-related molecule retinoic acid. J Immunol 2011; 187: 4170-4177.
34. Escribese MM, Conde E, Martin A, et al. Therapeutic effect of all-trans-retinoic acid (at-RA) on an autoimmune nephritis experimental model: Role of the VLA-4 integrin. BMC Nephrol 2007; 8: 3.
35. Pino-Lagos K, Guo Y, Brown C, et al. A retinoic acid-dependent checkpoint in the development of CD4+ T cell-mediated immunity. J Exp Med 2011; 208: 1767-1775.